Amgen Stock (NASDAQ:AMGN), Analyst Ratings, Price Targets, Predictions

The latest price target for Amgen (NASDAQ: AMGN) was reported by UBS on April 17, 2024. The analyst firm set a price target for $284.00 expecting AMGN to fall to within 12 months (a possible -10.97% downside). 42 analyst firms have reported ratings in the last year.

The latest analyst rating for Amgen (NASDAQ: AMGN) was provided by UBS, and Amgen maintained their neutral rating.

The last upgrade for Amgen Inc happened on December 21, 2023 when Daiwa Capital raised their price target to $320. Daiwa Capital previously had a neutral for Amgen Inc.

The last downgrade for Amgen Inc happened on October 31, 2022 when Barclays changed their price target from N/A to $234 for Amgen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Amgen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Amgen was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.

While ratings are subjective and will change, the latest Amgen (AMGN) rating was a maintained with a price target of $314.00 to $284.00. The current price Amgen (AMGN) is trading at is $319.00, which is out of the analyst’s predicted range.